XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2020
Jun. 30, 2019
Current assets:    
Cash and cash equivalents $ 163.7 $ 93.2
Marketable investment securities 54.1 43.7
Prepaid expenses 13.8 16.6
Inventory 29.1 31.4
Trade accounts receivable 68.1 133.9
Prepaid taxes   25.1
Other receivables 2.9 4.7
Total current assets 331.7 348.6
Property, plant and equipment, net 37.0 57.3
Operating lease right-of-use assets 66.0  
Long-term marketable investment securities 37.0 54.9
Intangibles, net 605.3 684.7
Goodwill 327.6 417.2
Total assets 1,404.6 1,562.7
Current liabilities:    
Accounts payable 21.7 33.3
Accrued liabilities 75.9 78.9
Current maturities of operating lease liabilities 13.5  
Short-term contingent consideration 3.1 3.4
Deferred revenue 32.8 2.2
Total current liabilities 147.0 117.8
Unrecognized tax benefits 23.5 21.7
Noncurrent operating lease liabilities 56.9  
Other long-term liabilities 4.3 7.8
Contingent consideration 3.7 10.4
Long-term debt 224.4 233.5
Long-term deferred taxes 26.6 82.6
Total liabilities 486.4 473.8
Commitments and contingencies
Stockholders’ equity:    
Common stock, 74.7 and 73.5 shares outstanding at June 30, 2020 and 2019 respectively 0.7 0.7
Additional paid-in capital 1,096.6 1,068.0
Accumulated other comprehensive loss (5.2) (5.4)
Retained earnings (accumulated deficit) (173.9) 25.6
Total Myriad Genetics, Inc. stockholders' equity 918.2 1,088.9
Total stockholders' equity 918.2 1,088.9
Total liabilities and stockholders’ equity $ 1,404.6 $ 1,562.7